Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02633111 · ClinicalTrials.gov registry record
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
A clinical trial of B-Cell Non-Hodgkin Lymphoma and Aggressive, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 501
- Enrollment target
- 12
- Study locations
NCT02633111: Active study of B-Cell Non-Hodgkin Lymphoma and Aggressive, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02633111 is a study of B-Cell Non-Hodgkin Lymphoma and Aggressive that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 501 participants, above the 109-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (360% higher). The trial reports 12 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02633111, a study of B-Cell Non-Hodgkin Lymphoma and Aggressive, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 501 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to determine whether a blood test can accurately detect whether if the participant's lymphoma has come back after completion of initial chemotherapy treatment for their aggressive B-cell Non-Hodgkin lymphoma. The purpose of the study is to see if MRD in blood samples can potentially replace CT scans after completion of chemotherapy in the future.
Primary Outcome
using the Sequenta diagnostic tool prior to detection using the conventional means (clinical exams and scans) in DLBCL patients.
Conditions Studied
Interventions
- DEVICE PET/CT
- OTHER collected at pre-treatment tumor biopsy
- OTHER Peripheral blood tests
Study Locations (12)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Cancer Center - Harrison
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Florida
- University of Miami - Miami
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- Md Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2015-10 |
| Est. Completion | 2026-10 |
What the registry record for NCT02633111 still lists
NCT02633111 is an observational study that tracks outcomes without assigning an intervention. The registered 501 participants enrollment target is mid-sized for trials with a published cap, above the 109-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (360% higher).
The record links to 2 conditions, with B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which PET/CT is the first listed.
NCT02633111 lists 12 locations in 6 states (New York, New Jersey, Florida).
Frequently Asked Questions
What is clinical trial NCT02633111 about?
NCT02633111 is a clinical study titled "DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas". The purpose of this study is to determine whether a blood test can accurately detect whether if the participant's lymphoma has come back after completion of initial chemotherapy treatment for their aggressive B-cell Non-Hodgkin lymphoma. The purpose of the study is to see if MRD in blood samples can...
What is the current status of trial NCT02633111?
This trial is currently active not recruiting. The enrollment target is 501 participants. The study started on 2015-10. Estimated completion is 2026-10.
What conditions does trial NCT02633111 study?
This clinical trial studies the following conditions: B-Cell Non-Hodgkin Lymphoma, Aggressive.
What interventions are being tested in trial NCT02633111?
The interventions under investigation include: PET/CT (DEVICE), collected at pre-treatment tumor biopsy (OTHER), Peripheral blood tests (OTHER).
Who is sponsoring clinical trial NCT02633111?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02633111 being conducted?
This trial has 12 study locations across Florida, Minnesota, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-Cell Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02633111's enrollment target sits among peer trials
501 1st of 24 higher than 24 of 24 other B-Cell Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other B-Cell Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RECRUITING · Phase 1
-
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
RECRUITING · Phase 1
-
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
RECRUITING · Phase 2
-
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06934525 · 501 participants · NA
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia